📊 SDGR Key Takeaways
Is Schrodinger, Inc. (SDGR) a Good Investment?
Schrodinger exhibits weak operational fundamentals with stagnant revenue growth (0% YoY) and unsustainable operating losses (-65.2% margin, -$166.9M absolute). While the strong balance sheet ($230.5M cash, zero debt) and positive free cash flow provide near-term resilience, the absence of revenue growth and persistent large-scale losses indicate structural operational challenges that threaten long-term viability without significant strategic improvement.
Why Buy Schrodinger, Inc. Stock? SDGR Key Strengths
- Strong balance sheet with $230.5M cash and zero long-term debt, providing 18+ months operational runway
- Positive free cash flow of $12.5M despite GAAP losses, indicating non-cash charges inflate net loss
- Respectable gross margin of 55.7% demonstrates pricing power and product-market traction at unit level
- Healthy liquidity metrics (2.75x current ratio) enable flexibility to fund operations and strategic initiatives
SDGR Stock Risks: Schrodinger, Inc. Investment Risks
- Stagnant revenue growth (0% YoY) in competitive pharmaceutical/biotech sector where expansion is critical
- Operating losses consuming 65.2% of revenue (-$166.9M operating loss on $255.9M revenue) are unsustainable
- Negative return metrics (ROE -28.4%, ROA -14.2%) indicate poor capital efficiency despite substantial equity base
- Deteriorating profitability trajectory: operating losses exceed revenue, creating path-to-profitability uncertainty
Key Metrics to Watch
- Quarterly revenue growth rate and customer/contract pipeline growth
- Operating expense ratio and quarterly path toward operating breakeven
- Monthly cash burn rate relative to remaining cash runway
- Gross margin trends by segment and customer retention/churn metrics
Schrodinger, Inc. (SDGR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.9% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.75x current ratio provides a solid financial cushion.
SDGR Profit Margin, ROE & Profitability Analysis
SDGR vs Healthcare Sector: How Schrodinger, Inc. Compares
How Schrodinger, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Schrodinger, Inc. Stock Overvalued? SDGR Valuation Analysis 2026
Based on fundamental analysis, Schrodinger, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Schrodinger, Inc. Balance Sheet: SDGR Debt, Cash & Liquidity
SDGR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Schrodinger, Inc.'s revenue has grown significantly by 137% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.54 reflects profitable operations.
SDGR Revenue Growth, EPS Growth & YoY Performance
SDGR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $35.3M | -$32.8M | $-0.45 |
| Q2 2025 | $47.3M | -$43.2M | $-0.59 |
| Q1 2025 | $36.6M | -$54.7M | $-0.76 |
| Q3 2024 | $35.3M | $4.3M | $-0.52 |
| Q2 2024 | $35.2M | $4.3M | $0.06 |
| Q1 2024 | $36.6M | -$54.7M | $-0.76 |
| Q3 2023 | $37.0M | $4.3M | $-0.56 |
| Q2 2023 | $35.2M | $4.3M | $0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Schrodinger, Inc. Dividends, Buybacks & Capital Allocation
SDGR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Schrodinger, Inc. (CIK: 0001490978)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SDGR
What is the AI rating for SDGR?
Schrodinger, Inc. (SDGR) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SDGR's key strengths?
Claude: Strong balance sheet with $230.5M cash and zero long-term debt, providing 18+ months operational runway. Positive free cash flow of $12.5M despite GAAP losses, indicating non-cash charges inflate net loss.
What are the risks of investing in SDGR?
Claude: Stagnant revenue growth (0% YoY) in competitive pharmaceutical/biotech sector where expansion is critical. Operating losses consuming 65.2% of revenue (-$166.9M operating loss on $255.9M revenue) are unsustainable.
What is SDGR's revenue and growth?
Schrodinger, Inc. reported revenue of $255.9M.
Does SDGR pay dividends?
Schrodinger, Inc. does not currently pay dividends.
Where can I find SDGR SEC filings?
Official SEC filings for Schrodinger, Inc. (CIK: 0001490978) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SDGR's EPS?
Schrodinger, Inc. has a diluted EPS of $-1.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SDGR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Schrodinger, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SDGR stock overvalued or undervalued?
Valuation metrics for SDGR: ROE of -28.4% (sector avg: 15%), net margin of -40.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SDGR stock in 2026?
Our dual AI analysis gives Schrodinger, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SDGR's free cash flow?
Schrodinger, Inc.'s operating cash flow is $13.9M, with capital expenditures of $1.4M. FCF margin is 4.9%.
How does SDGR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -40.4% (avg: 12%), ROE -28.4% (avg: 15%), current ratio 2.75 (avg: 2).